Abstract: A coating material is a coating material used for applying a coating film formed on a coating made of a zinc-containing material formed in contact with a surface of a metal material and is composed of a binder, a first inorganic material, and a second inorganic material. The binder is composed of an organic resin and does not contain metallic zinc and a zinc alloy. The first inorganic material is composed of a sulfate having a solubility lower than 5 g/100 mL with respect to water. The second inorganic material is soluble in water, exhibits alkalinity if dissolved in water, and has a solubility lower than 5 g/100 mL with respect to water.

Abstract: A semiconductor wafer includes pairs of semiconductor dies having test pads which are electrically coupled to each other to enable testing of pairs of semiconductor dies together at the same time. In this way, even wafers having large numbers of semiconductor dies can be tested with a semiconductor test assembly in a single touch-down test process.

Abstract: A semiconductor wafer includes pairs of semiconductor dies having test pads which are electrically coupled to each other to enable testing of pairs of semiconductor dies together at the same time. In this way, even wafers having large numbers of semiconductor dies can be tested with a semiconductor test assembly in a single touch-down test process.

Abstract: A semiconductor wafer includes pairs of semiconductor dies having test pads which are electrically coupled to each other to enable testing of pairs of semiconductor dies together at the same time. In this way, even wafers having large numbers of semiconductor dies can be tested with a semiconductor test assembly in a single touch-down test process.

Abstract: The present invention provides a composition comprising an ionic liquid and a poorly absorbable drug, wherein the ionic liquid is prepared from an anion and a cation, the anion is an organic acid having 3 to 7 carbon atoms, and the cation is selected from the group consisting of arginine, meglumine, trometamol and diethanolamine, which remarkably improves the absorbability of the poorly absorbable drug.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody or fusion protein thereof. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody fusion protein thereof.

Abstract: In a first step, a sample liquid is fabricated by mixing a sample formed of a polyester or decomposition products of a polyester into a solvent. The solvent used here contains chloroform and 2,2,2-trifluoroethanol and has an organic base added thereto. The organic base is at least one of a primary amine, a secondary amine, a tertiary amine and a heterocyclic amine. Next, in a second step, each of the amount of the terephthalic acid terminal and the amount of the hydroxy group terminal in the sample liquid is measured through a nuclear magnetic resonance spectroscopy aiming at hydrogen atoms. Subsequently, in a third step, the number average molecular weight of the sample is calculated from the amount of the terephthalic acid terminal and the amount of the hydroxy group terminal measured in the second step.

Abstract: A coating material is allowed to contain a sulfate having a higher degree of solubility in water than that of calcium sulfate. The sulfate is an additive for coating materials which is used for reducing the consumption of zinc (including zinc oxide) in a coating film formed from the coating material and the corrosion of a base material when the coating film is scratched. The content of the sulfate can be 0.004 to 0.65 mol per 100 g of the content of zinc. Alternatively, the content of the sulfate may be 0.006 to 0.186 mol per 100 g of a heating residue (except for the sulfate added) of a coating film.

Abstract: In a first step, a sample liquid is fabricated by mixing a sample formed of a polyester or decomposition products of a polyester into a solvent. The solvent used here contains chloroform and 2,2,2-trifluoroethanol and has an organic base added thereto. The organic base is at least one of a primary amine, a secondary amine, a tertiary amine and a heterocyclic amine.

Abstract: An accelerated corrosion test apparatus includes: a moisture sensor disposed near the reinforcing steel exposed from a cracked portion of concrete; a weight measuring instrument that measures a weight of the reinforced concrete specimen; and a control terminal that is connected both to the moisture sensor and to the weight measuring instrument and controls a temperature and humidity control device, thereby alternately and repeatedly performing a wetting step of supplying moisture to the inside of a crack in the cracked concrete, and a drying step of removing moisture in the inside of the crack and moisture on the exposed surface of the reinforcing steel, wherein the control terminal terminates the wetting step and starts the drying step when moisture is detected in the moisture sensor, or when change in slope of weight change of the reinforced concrete specimen is detected, after the start of the wetting step.

Abstract: In a first step, a sample formed of a polyester or decomposition products of a polyester is dissolved in a pretreatment liquid containing 1,1,1,3,3,3-hexafluoro-2-propanol and an organic base to produce a reaction product of the sample, and in a second step, the obtained reaction product is mixed into a solvent (measurement solvent) containing deuterated chloroform and deuterated 1,1,1,3,3,3-hexafluoro-2-propanol to fabricate a sample liquid. Next, in a third step, the amount of the reaction product in the sample liquid is measured through NMR aiming at hydrogen atoms to determine the amount of an acid anhydride structure in the sample.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.

Abstract: A paint contains a zinc powder, a binding agent made of an organic resin, and an inorganic material that is water-soluble and exhibits alkalinity when being dissolved in water. The inorganic material can be, for example, one that provides a saturated aqueous solution having a pH of 12 or less. For example, the basic substance may be barium carbonate, barium hydrogen phosphate, beryllium carbonate, calcium carbonate, calcium hydrogen phosphate, calcium phosphate, lithium carbonate, lithium phosphate, magnesium carbonate, basic magnesium carbonate, magnesium hydroxide, magnesium oxide, or magnesium phosphate.

Abstract: This invention relates to factor B inhibitors or nucleic acid molecules encoding thereof and selective inhibition of the alternative pathway (AP) of the complement system using said factor B inhibitors or nucleic acid molecules encoding thereof or compositions thereof. The invention also provides methods of treating an AP complement-mediated disease or AP complement-mediated disorder in a subject by administering a therapeutically effective amount of the factor B inhibitor or nucleic acid molecules encoding thereof or composition thereof.

Abstract: A paint comprises a zinc powder, a binder made of an organic resin, calcium sulfate, and a dispersant, wherein a content of the calcium sulfate is 0.046 to 0.186 mol per 100 g of a heating residue of a coating film (from which sulfate added is excluded), a weight ratio of zinc to a dried coating film from which the calcium sulfate is excluded is 70 wt %, a weight ratio of the dispersant to the calcium sulfate is 0.05 to 0.5 wt %, and the dispersant is constituted by at least one of a block copolymer having a basic group with pigment affinity, an oil-soluble non-ionic active agent, and a polyether-modified silicone.

Abstract: This invention relates to inhibition of the complement signaling using an anti-C5 antibody. Specifically, the invention relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the individual with an anti-C5 antibody.

Abstract: This invention relates to selective inhibition of the alternative pathway (AP) of the complement system using an anti-factor D antibody. Specifically, the invention relates to methods of treating an AP-mediated disease or AP-mediated disorder in an individual by contacting the individual with an anti-factor D antibody.

Abstract: In a pretreatment method, in first step, a sample is dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol to prepare a first solution. In second step, an organic base is added to the first solution to prepare a second solution. In third step, the second solution is heated to obtain a substance in which an anhydrous oxide structure in the sample has been decomposed. In a fourth step, an organic solvent that has a higher boiling point than that of 1,1,1,3,3,3-hexafluoro-2-propanol and is compatible (miscible) with 1,1,1,3,3,3-hexafluoro-2-propanol is added to the second solution to prepare a third solution.

Abstract: In a pretreatment method, in a first step, a sample is dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol to prepare a first solution. In a second step, an organic base that has a lower boiling point than that of HFIP is added to the first solution to prepare a second solution. In a third step, the second solution is heated to obtain a substance in which an anhydrous oxide structure in the sample has been decomposed. In a fourth step, chloroform is added to the second solution to prepare a third solution.

Abstract: Provided are a door trim attached on a vehicle cabin side of a vehicle door and including a storage recess curved outward in a vehicle-width direction, and a release switch disposed in the storage recess and pushed in a predetermined operating direction to output a latch release signal to an actuator that moves a latch member. The latch switch is completely stored in the storage recess, and the operating direction is tilted toward the rear of the vehicle relative to an axis extending outward in the vehicle-width direction.